Page 12 - Read Online

Peri. J Cancer Metastasis Treat 2019;5:40 I http://dx.doi.org/10.20517/2394-4722.2019.14 Page 7 of 7

31. Furukawa J, Miyake H, Kusuda Y, Fujisawa M. Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell
renal cell carcinoma treated with a tyrosine kinase inhibitor. Int J Clin Oncol 2015;20:351-7.
32. Kim HS, Yi SY, Jun HJ, Lee J, Park JO, et al. Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology
2007;73:192-7.
33. Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, et al. Performance status in patients with hepatocellular carcinoma: determinants,
prognostic impact, and ability to improve the barcelona clinic liver cancer system. Hepatology 2013;57:112-9.
34. Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and
differential diagnosis. Support Care Cancer 2000;8:192-7.
35. Chawla A, Sterns RH, Nigwekar SU, Cappuccio JD. Mortality and serum sodium: do patients die from or with hyponatremia. Clin J Am
Soc Nephrol 2011;6:960-5.
36. Shepshelovich D, Leibovitch C, Klein A, Zoldan S, Milo G, Shochat T et al. The syndrome of inappropriate antidiuretic hormone
secretion: distribution and characterization according to etiologies. Eur J Intern Med 2015;26:819-24.
37. Berardi R, Santoni M, Newsom-Davis T, Caramanti M, Rinaldi S, et al. Hyponatremia normalization as an independent prognostic factor
in patients with advanced non-small cell lung cancer treated with first-line therapy. Oncotarget. 2017;8:23871-9.
38. Penttilä P, Bono P, Peltola K, Donskov F. Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated
with everolimus: prognostic impact. Acta Oncol 2018;57:1580-5.
39. Corona G, Giuliani C, Verbalis JG, Forti G, Maggi M, et al. Hyponatremia improvement is associated with a reduced risk of mortality:
evidence from a meta-analysis. PLoS One 2015;10:e0124105.
40. Havard M, Dautry F, Tchénio T. A dormant state modulated by osmotic pressure controls clonogenicity of prostate cancer cells. J Biol
Chem 2011;286:44177-86.
41. Benvenuti S, Deledda C, Luciani P, Modi G, Bossio A, et al. Low extracellular sodium causes neuronal distress independently of reduced
osmolality in an experimental model of chronic hyponatremia. Neuromolecular Med. 2013;15:493-503.
42. Chau LY. Heme oxygenase-1: emerging target of cancer therapy. J Biomed Sci 2015;22:22.
43. Yadav B, Greish K. Selective inhibition of hemeoxygenase-1 as a novel therapeutic target for anticancer treatment. J Nanomedic
Nanotechnol 2011;S4:5.
44. Bhandari S, Peri A, Cranston I, McCool R, Shaw A, Glanville J, et al. A systematic review of known interventions for the treatment of
chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans. Clin Endocrinol (Oxf) 2017;86:761-71.
45. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for
hyponatremia. N Engl J Med 2006;355:2099-112.
46. Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of
inappropriate antidiuretic hormone secretion. Eur J Endocrinol 2011;164:725-32.